Deutsche Bank upgraded Boston Scientific (BSX) to Buy from Hold with a price target of $108, up from $87. Boston Scientific’s :story has become simpler” following Johnson & Johnson’s (JNJ) Varipulse getting pulled from the shelves, the analyst tells investors in a research note. The firm says that as one of the “best-in-class medtech names,” Boston Scientific is poised again to outperform in 2025. For both short-term and long-term investors, the recent news about Varipulse “removes the major overhang” in 2025 and can allow Boston Scientific to continue to “grind higher throughout the year,” contends Deutsche Bank.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $110 from $100 at Bernstein
- Boston Scientific Bolt Medical acquisition ‘checks right boxes,’ JPMorgan says
- J&J pause ‘very good’ for Boston Scientific, says Piper Sandler
- Early notable gainers among liquid option names on January 8th
- Boston Scientific to acquire Bolt Medical for upfront payment of $443M